Compare Victoria's Secret & Co (VSXY) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Victoria's Secret & Co vs GeneDx Holdings Corp — how do they compare? Victoria's Secret & Co trades at $76 (market cap $6.04B), while GeneDx Holdings Corp trades at $86.53 (market cap $2.58B). The key difference: Victoria's Secret & Co is far larger — about 2.3× GeneDx Holdings Corp's market cap, and Victoria's Secret & Co is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals.
| VSXY | WGS | |
|---|---|---|
Market Cap | $6.04B | $2.58B |
Sector | Consumer Cyclical | Technology |
52-Week High | $99.97 | $167.51 |
52-Week Low | $25.56 | $34.51 |
Enterprise Value | $8.42B | $2.61B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Victoria's Secret (VSXY) trades at $78.47, up 3.85% over 24 hours, with a bearish technical signal despite recent earnings beats. The stock shows strong profitability metrics, including a 45.27% ROE and 39.57% gross margin, but faces revenue stagnation and negative net cash flow trends. Recent news highlights PINK brand growth and Q2 2026 earnings surpassing estimates, though the stock fell due to sales concerns.
The outlook is mixed: analyst consensus is bullish with a $94.86 price target, but technical weakness and competitive pressures pose risks. Earnings momentum and cost management are key drivers for upside, while investor sentiment remains cautious amid volatility.
WGS trades at $85.87, down 0.14% today, with a bullish technical signal from moving averages and support at $84. The company reported Q2 2026 revenue of $114.4M, beating estimates, and returned to adjusted profitability early. However, net income remains negative at -$106M for 2026, with high valuation multiples like EV/EBITDA of 161.17. Recent news highlights partnerships and product launches, such as the NPC GenomeComplete initiative with Beren Therapeutics.
Outlook is mixed: strong analyst buy consensus (90.9%) and institutional interest support upside, but profitability challenges and a class action lawsuit pose risks. Revenue growth and operational improvements are key catalysts, yet high debt-to-asset ratios and negative margins require monitoring for sustained recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Victoria's Secret & Co
Victoria's Secret & Co is a specialty retailer of lingerie, pajamas, and beauty products with prestige fragrances and body care. It serves customers at its Lingerie and Beauty stores around the globe and online enabling them to shop the brand anywhere and anytime.
Read more on VSXY →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
